Supplementary Figure 1 from <i>kras</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in ≪i>braf</i>–wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

PDF file - 108KB, Predictive value of specific KRAS mutations in patients with BRAF-wild type resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy with vs without cetuximab. Unadjusted hazard ratios (HR) for disease-free survival by KRAS mutation strata are shown for patients who were randomized during the period when KRAS-mutated and -wild type tumors were eligible. HR < 1 indicates benefit from cetuximab. No estimates produced due to insufficient sample size in one subgroup.